Fig. 4: T-cell response to COVID-19 BNT162b2 vaccine.
From: Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
A T-cell response was assessed by IFN-γ ELISPOT at baseline (before first BNT162b2 vaccination, d0) and 2 weeks after the second BNT162b2 vaccination (d42), n = 68. T-cell response against CMV, EBV, Influenza virus, and Tetanus toxoid (CEF/CEFT, left panel). T-cell response against SARS-CoV-2 spike protein (S), or its receptor binding domain (RBD), or against membrane protein (M) (right panel). Cross indicates missing data. CLL chronic lymphocytic leukemia, AL MDS acute leukemia and myelodysplastic syndrome, MPN myeloproliferative neoplasm. B T-cell response against S and RBD at d42 according to patients’ gender. C Correlation between T-cell responses against S and RBD and anti-S IgG at d42.
